Not Many Biotech Companies Are Showing Growth – (GILD, THLD, GNOM, AMGN)


The NYSE Arca Biotech index yesterday hit its best level on record, as investors continued to seek out the group for its above average growth forecast. Cowen & Co’s Eric Schmidt said that there are simply not many industry players growing and as a result they have seen increasingly growth fund managers taking an interest in biotech, where corporate earnings are not correlated with the global environment.


Gilead Sciences, Inc. (NASDAQ:GILD)
broke 52-weeks high price after Wall Street analysts including Schmidt and colleagues from UBS and JPMorgan all provided bullish views on the company’s growth outlook.

To have a quick look on this stock’s price history, beta used to measure the volatility or systematic risk in comparison to the market as a whole was 0.45 and the percentage change in the price over the last fifty two weeks remained at +61.12%. The price range in those 52 weeks had a highest hit of $66.27 on Sep 17, 2012 while lowest level during that period was $34.45 on Nov 21, 2011.

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) faced a steep fall on pancreatic cancer drug survival data. The stock moved up 473.77% in this year and its price history showed most recently beta was at 2.38. Overall during the last 12 months, the percentage change in the price was 302.30%, hitting the highest of $9.28 on Sep 05, 2012 while lowest level in that period was $1.18 on Dec 21, 2011.

Complete Genomics, Inc. (NASDAQ:GNOM) jumped yesterday after a deal to get sold to a Chinese company. Its shares rallied 3.07% so far in 2012. The stock percentage change in the price over the last fifty two weeks remained at -56.61%. The price range in that 1-year period had a best hit of $7.45 on Sep 20, 2011 while lowest level in the same period was $1.57 on May 21, 2012.

Amgen, Inc. (NASDAQ:AMGN) recovered from previous fall as RBC Capital gave Outperform rating to the stock. So far, the share price of this stock jumped 29.77% in this year and stock’s price history revealed that beta was maintained at 0.55 and the percentage change in the price over the last fifty two weeks remained as 43.09%.


Leave a Reply

Your email address will not be published. Required fields are marked *